Michael N. Maisey – författare

Essential for students, science and medical graduates who want to understand the basic science of Positron Emission Tomography (PET), this book describes the physics, chemistry, technology and overview of the clinical uses behind the science of PET and the imaging techniques it uses. In recent years, PET has moved from high-end research imaging tool used by the highly specialized to an essential component of clinical evaluation in the clinic, especially in cancer management. Previously being the realm of scientists, this book explains PET instrumentation, radiochemistry, PET data acquisition and image formation, integration of structural and functional images, radiation dosimetry and protection, and applications in dedicated areas such as drug development, oncology, and gene expression imaging. The technologist, the science, engineering or chemistry graduate seeking further detailed information about PET, or the medical advanced trainee wishing to gain insight into the basic science of PET will find this book invaluable.

This book is primarily repackaged content from the Basic Science section of the ''big'' Valk book on PET. It contains new, completely revised and unchanged chapters covering the "basic sciences" section of the main book - total 18 chapters:

2 new (chapters 1, 16)8 completely revised (chapters 4, 5, 8, 13, 14, 15, 17, 18)3 minor corrections (chapters 2, 6, 11)5 unchanged (chapters 3, 7, 9, 10, 12)

The use of positron emission tomography (PET) in clinical practice is key to the s- cessful management of many patients with a wide variety of diseases. Whereas in the 1980s and 1990s nuclear medicine physicians struggled to convince other doctors about the potential clinical value of PET, it is now a challenge to keep up with the requests of our clinical colleagues for the various applications of PET. In fact, in most cases the barriers are now related to reimbursement for a given PET procedure. At the time this foreword was written, many FDG/PET procedures are reimbursable, and the U.S. National PET Registry, which is about to be implemented, will allow FDG/PET imaging data to accumulate on rare tumors, while allowing for Center for Medicare and Medicaid Services (CMS) reimbursement. The challenges are now shifting toward solving some of the limitations of FDG/PET through the use of next generation inst- mentation and newer tracers that hold the promise of improving on what is already a remarkable achievement with FDG/PET. It is my hope that there will in fact be an enormous growth of nuclear medicine driven by new imaging tracers that will fuel a growing number of clinical applications.

The use of positron emission tomography (PET) in clinical practice is key to the s- cessful management of many patients with a wide variety of diseases. Whereas in the 1980s and 1990s nuclear medicine physicians struggled to convince other doctors about the potential clinical value of PET, it is now a challenge to keep up with the requests of our clinical colleagues for the various applications of PET. In fact, in most cases the barriers are now related to reimbursement for a given PET procedure. At the time this foreword was written, many FDG/PET procedures are reimbursable, and the U.S. National PET Registry, which is about to be implemented, will allow FDG/PET imaging data to accumulate on rare tumors, while allowing for Center for Medicare and Medicaid Services (CMS) reimbursement. The challenges are now shifting toward solving some of the limitations of FDG/PET through the use of next generation inst- mentation and newer tracers that hold the promise of improving on what is already a remarkable achievement with FDG/PET. It is my hope that there will in fact be an enormous growth of nuclear medicine driven by new imaging tracers that will fuel a growing number of clinical applications.

Essential for students, science and medical graduates who want to understand the basic science of Positron Emission Tomography (PET), this book describes the physics, chemistry, technology and overview of the clinical uses behind the science of PET and the imaging techniques it uses. In recent years, PET has moved from high-end research imaging tool used by the highly specialized to an essential component of clinical evaluation in the clinic, especially in cancer management. Previously being the realm of scientists, this book explains PET instrumentation, radiochemistry, PET data acquisition and image formation, integration of structural and functional images, radiation dosimetry and protection, and applications in dedicated areas such as drug development, oncology, and gene expression imaging. The technologist, the science, engineering or chemistry graduate seeking further detailed information about PET, or the medical advanced trainee wishing to gain insight into the basic science of PET will find this book invaluable. This book is primarily repackaged content from the Basic Science section of the 'big' Valk book on PET. It contains new, completely revised and unchanged chapters covering the "basic sciences" section of the main book - total 18 chapters:2 new (chapters 1, 16)8 completely revised (chapters 4, 5, 8, 13, 14, 15, 17, 18)3 minor corrections (chapters 2, 6, 11)5 unchanged (chapters 3, 7, 9, 10, 12)

The use of positron emission tomography (PET) in clinical practice is key to the s- cessful management of many patients with a wide variety of diseases. Whereas in the 1980s and 1990s nuclear medicine physicians struggled to convince other doctors about the potential clinical value of PET, it is now a challenge to keep up with the requests of our clinical colleagues for the various applications of PET. In fact, in most cases the barriers are now related to reimbursement for a given PET procedure. At the time this foreword was written, many FDG/PET procedures are reimbursable, and the U.S. National PET Registry, which is about to be implemented, will allow FDG/PET imaging data to accumulate on rare tumors, while allowing for Center for Medicare and Medicaid Services (CMS) reimbursement. The challenges are now shifting toward solving some of the limitations of FDG/PET through the use of next generation inst- mentation and newer tracers that hold the promise of improving on what is already a remarkable achievement with FDG/PET. It is my hope that there will in fact be an enormous growth of nuclear medicine driven by new imaging tracers that will fuel a growing number of clinical applications.